Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Wendy Petit"'
Autor:
Ronnie Wang, R. Riese, Sriram Krishnaswami, Sujatha Menon, Wendy Petit, Haihong Shi, Christine Alvey
Publikováno v:
Clinical Pharmacology in Drug Development
Tofacitinib is an oral Janus kinase inhibitor. Tofacitinib metabolism is primarily mediated by cytochrome P450 3A4. This phase 1 randomized, open‐label, 2‐way crossover study (NCT01137708) evaluated the effect of tofacitinib 30 mg twice daily on
Autor:
James R. Gosset, Wendy Petit, Nicola Clear, David S. Reynolds, Pierre-Philippe Saintot, Kelly Conlon, Sonia Roberts, Jennifer C. Gardiner, Paul Alan Glossop, Susie Collins, Kevin Beaumont, Michael Postlethwaite, Wendy J. Winchester, Michael John Palmer, Sophie Glatt, Tomomi Matsuura, Andrews Mark David, Katrina Gore
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 351(2)
The transient receptor potential (subfamily M, member 8; TRPM8) is a nonselective cation channel localized in primary sensory neurons, and is a candidate for cold thermosensing, mediation of cold pain, and bladder overactivity. Studies with TRPM8 kno
Autor:
Sarah Tweedy, Vanitha Sekar, Rebecca Mack, Samantha Abel, Monika Schöller-Gyüre, Richard M. W. Hoetelmans, Caroline E. Ridgway, Wendy Petit, Thomas N. Kakuda, Noella Ndongo, John D. Davis, Julia Hamlin
The effects of darunavir-ritonavir at 600 and 100 mg twice daily (b.i.d.) alone, 200 mg of etravirine b.i.d. alone, or 600 and 100 mg of darunavir-ritonavir b.i.d. with 200 mg etravirine b.i.d. at steady state on the steady-state pharmacokinetics of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2dc7b44c73242d4ae019e324b26cf44d
https://europepmc.org/articles/PMC3088221/
https://europepmc.org/articles/PMC3088221/